Managed Entry Agreements: Paying for a Drug Before the Evidence Is In

Managed entry agreements let a health system cover an expensive new medicine before the evidence is settled. Financial versions simply cut the price through confidential discounts or rebates. Outcomes-based versions tie payment to whether the drug works, but measuring that demands registries and monitoring that are costly, slow, and often inconclusive.

The appeal is access now, with the risk of being wrong shared rather than carried alone. The difficulty is that proving who succeeded and who failed is slow and often inconclusive, which is why the more ambitious version is the harder one to keep running. This is general education about how health systems pay for medicines, not medical advice.

Why a payer signs one

When a new drug arrives, the evidence behind it is often thinner than the price implies. A trial may show a benefit on a surrogate marker measured over months, while the payer is asked to fund the drug for years, in patients the trial never enrolled, at a cost that can reach six figures per person. Facing that gap, a payer has two blunt choices. It can withhold coverage until stronger evidence appears, which delays access for people who might benefit, or it can pay in full and absorb the risk that the money buys little. The managed entry agreement is the negotiated middle. The OECD's 2019 review of these arrangements across OECD countries and EU member states, built on a survey and interviews with experts in twelve countries, frames them as a way to grant access while managing uncertainty about a product's value and its budget impact (Wenzl and Chapman).

Two families, very different demands

The financial family is the workhorse. Straight price cuts, budget caps, and volume rebates are used or have been used in at least two-thirds of OECD and EU countries, according to that review, because they are easy to write and easy to enforce. The arithmetic of a discount does not depend on any patient's outcome. The performance family is where the idea gets interesting and where it gets hard. Its two commonest designs are payment by result, which reimburses the manufacturer only for patients who respond, and coverage with evidence development, which grants temporary reimbursement on the condition that new data are gathered while the drug is in use, with the coverage decision revisited once those data arrive.

Both performance designs make a promise that sounds unarguable: pay for results rather than for volume. To keep the promise, though, someone has to define a response, measure it in every treated patient, adjudicate the borderline cases, and trigger the refund. That machinery is the whole difference between the two families, and reviews of the broader European and United States experience note that a substantial share of performance schemes cluster in oncology and lapse or go unrenewed within a few years.

The monitoring problem

Measuring outcomes at scale is the part that quietly defeats these agreements. It requires a registry that captures each eligible patient, records the agreed endpoint, and links it to a payment, plus the staff to run it and the clinicians to enter data during real appointments. The OECD review is direct about the resulting strain. Its authors flag a limited ability to actually reduce uncertainty, because the real-world data collected are often of uncertain quality or hard to interpret; a difficulty in acting on the results when a coverage decision has to be revisited; and an administrative burden concentrated in exactly that data collection and analysis (Wenzl and Chapman).

The financial record supports the caution. Italy operates a national registry system built for this purpose, and a study of sixty-two medicines under managed entry agreements there between 2019 and 2021 found that all the paybacks combined recovered roughly 327 million euros, about 0.9 percent of what public health facilities spent on medicines over those three years. Outcome-based agreements returned less money than the simpler financial ones, even though they demand far more to administer, and the authors concluded there is limited evidence that these agreements lower spending overall. The performance version asks the most and, on that evidence, returned the least.

The confidentiality trade-off

There is a second, subtler cost. Financial agreements usually work by keeping the real price secret: the list price stays high while an undisclosed rebate flows back to the payer. That secrecy is what lets a manufacturer offer one country a deep cut without having to offer it everywhere, since many systems set their own prices by referencing the published prices elsewhere. The same secrecy blocks independent evaluation. If no one outside the negotiation can see what was paid or what was recovered, no one can judge whether the deal was good, and the confidentiality itself becomes a barrier to independent evaluation, a point the OECD review names plainly. A tool meant to manage uncertainty can end up hiding the evidence that would resolve it.

How to read the announcements

When a health system announces a deal to cover a costly new therapy, the useful questions are the same each time. Is the arrangement financial or outcomes-based, and if it claims to tie payment to results, what counts as a result and who verifies it? Is there a registry capable of measuring that, or is the monitoring aspirational? And can anyone outside the room ever check what the system actually paid? None of this makes managed entry agreements a bad idea. They are a reasonable response to a genuine bind, and for one-off high-cost therapies they may be one of the few ways to reconcile early access with affordability. But the more a deal promises to pay strictly for value, the more monitoring it silently requires, and the evidence so far suggests that promise is easier to sign than to keep.